Know Cancer

forgot password

The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

Phase 1/Phase 2
Open (Enrolling)
Diarrhea, Medullary Thyroid Cancer

Thank you

Trial Information

The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

Inclusion Criteria:

- Patients with medullary thyroid cancer

- Men and women from all ethnic and racial groups

- Diarrhea ( >=3 loose bowel movements per day)

- Duration of diarrhea of at least 1 week

Exclusion Criteria:

- Patients with MEN 2b (since these patients may have megacolon)

- Patients taking any clay products

- History of significant neurological or psychiatric disorders that would impede giving
consent, treatment, or follow up.

- Patients who cannot comply with medications

- Patients whose current medication schedule would not permit an approximate 2 hour
window between administration of CASAD and other scheduled medications.

- Pregnancy or lactation

- Patients receiving systemic chemotherapy (includes tyrosine kinase inhibitors)

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Efficacy in treatment of diarrhea

Outcome Description:

To evaluate the efficacy of CASAD 3 grams per day in reducing the severity of diarrhea after 1 week of treatment in patients with MTC.

Outcome Time Frame:

1 week

Safety Issue:



United States: Food and Drug Administration

Study ID:

SAL 2012-0584



Start Date:

November 2012

Completion Date:

December 2013

Related Keywords:

  • Diarrhea
  • Medullary Thyroid Cancer
  • Diarrhea
  • Medullary thyroid cancer
  • Thyroid Neoplasms
  • Diarrhea
  • Thyroid Diseases



MD Anderson Cancer CenterHouston, Texas  77030-4096